Nathan Ihle
About Nathan Ihle
Nathan Ihle, Senior Vice President at Bolt Biotherapeutics
Nathan Ihle serves as the Senior Vice President of Pharmaceutical Operations at Bolt Biotherapeutics, a position he has held since 2019. With nearly three decades of experience in pharmaceutical research and development, particularly in cancer drug development, Ihle brings a wealth of knowledge and expertise to his role. His extensive background in both scientific and strategic positions solidifies his leadership in the company.
Nathan Ihle's Experience in Pharmaceutical R&D
Nathan Ihle has accumulated nearly 30 years of experience in pharmaceutical R&D, focusing primarily on cancer drug development. His career includes significant roles such as the vice president of manufacturing strategy at Immunomedics, Inc. and a long tenure at Seattle Genetics, Inc., where he served as the vice president of CMC strategy and management for 16 years. This extensive background underscores his expertise in developing and implementing critical drug development strategies.
Nathan Ihle's Career and Founding of Ihle CMC Solutions
Prior to joining Bolt Biotherapeutics, Nathan Ihle founded and served as the principal at Ihle CMC Solutions. His role involved providing consultancy services in chemistry, manufacturing, and controls (CMC) strategies. This venture allowed him to leverage his deep understanding of pharmaceutical manufacturing processes and contributed to the industry's advancements in drug development.
Nathan Ihle's Academic Background
Nathan Ihle completed his doctorate in organic chemistry from Stanford University. Following his doctoral studies, he undertook post-doctoral work at the University of California, Berkeley as an American Cancer Society Postdoctoral fellow. This strong academic foundation in organic chemistry and cancer research has been instrumental in shaping his career in pharmaceutical research and development.
Roles at Seattle Genetics (Seagen) and Immunomedics (Gilead Sciences)
Nathan Ihle has held critical roles in notable pharmaceutical companies. At Seattle Genetics, Inc. (now Seagen), he worked for 16 years as the vice president of CMC strategy and management. Additionally, he served as the vice president of manufacturing strategy at Immunomedics, Inc., which is now part of Gilead Sciences. These positions involved key responsibilities in manufacturing strategies and CMC management, emphasizing his strategic influence in pharmaceutical operations.